Sun Pharma up over 2% on deal with US-based InSite Vision
Sun Pharma's stock gained over 2 percent Wednesday as the company has entered into an agreement with InSite Vision to acquire the US-based eyecare firm for around USD 48 million plus related debt and other transaction costs to strengthen its branded ophthalmic portfolio in the American market.
Sep 16, 2015, 18:03 PM IST